O-RAN-ALLIANCE-E.V.
18.2.2021 23:38:13 CET | Business Wire | Press release
As of January 2021, the O-RAN ALLIANCE welcomes LG U+ as its 28th operator member. With strong support by its expanding number of contributors, the alliance now counts more than 260 companies from around the globe, building a foundation and unifying the Radio Access Networks (RAN) industry towards open, intelligent, virtualized and fully interoperable RAN solutions.
O-RAN Open Summit (Virtual) Complements the O-RAN Demos at MWC Shanghai 2021
For latest updates on the evolution of open RAN, the O-RAN ALLIANCE invites interested industry participants to the O-RAN Open Summit . This compact virtual event will open with operator executives delivering a summary of O-RAN’s progress and developments. Subsequent keynotes and panel discussions with major O-RAN players will summarize the achievements and next steps in the O-RAN specification effort, testing and integration, and delivery of open software for the RAN.
The O-RAN Open Summit virtual event is scheduled for February 25, 2021 from 9:00-11:00pm China Standard Time (8:00-10:00am EST, 14:00-16:00 CET). For more information and to join the summit free of charge, please visit our website .
O-RAN Demonstrations at MWC Shanghai 2021 and at the O-RAN Virtual Showcase
Two O-RAN demonstrations are planned to be presented at the MWC Shanghai 2021:
- Sageran is demonstrating a complete O-RAN white-box small cell solution based on an x86 platform with an FPGA Accelerator card that showcases a stand-alone end-to-end use case using white box hardware for an indoor cell which supports MIMO with 4T4R. The demo is hosted at MWC Shanghai 2021 by Sageran, booth N2.C114 , as well as at the O-RAN Virtual Exhibition .
- VIAVI and Rohde & Schwarz are jointly demonstrating validation of open fronthaul performance. As network operators adopt disaggregated, multi-vendor networks, rigorous testing of performance and interoperability must accompany conformance testing. This demo showcases generation and delivery of typical standards based testcase IQ data to the O-RU utilizing the Lower Layer Split Option 7.2x fronthaul interface with the VIAVI TM500 O-RU Tester. Moreover, uplink and downlink fronthaul logs are captured, and RF signal generation and capture are performed using the Rohde & Schwarz VSG and VSA hardware with VSE Software for RF and IQ signal analysis. Testcase workflow is simplified for the end user utilizing the VIAVI O-RU Test Manager, providing a single point of test control. The demo is hosted at MWC Shanghai 2021 by VIAVI Solutions, booth N1.B137 , as well as at the O-RAN Virtual Exhibition .
5 more virtual demos for MWC Shanghai 2021 have enriched the O-RAN Virtual Exhibition :
- ITRI is demonstrating traffic steering xApps and Near-Real-Time Radio Intelligent Controller platform utilizing E2 procedures to monitor cell and UE metrics generated by RAN simulator and to offload some UE to neighbor cells such that the A1 policy is guaranteed.
- NVIDIA and VMWare are jointly demonstrating PoC of Aerial 5G gNB Layer-1 orchestration on VMWare telco cloud platform. This demo showcases NVIDIA Aerial SDK as cloud native function, with docker containers and Kubernetes manifests. Aerial cuBB onboarded to VMWare telco cloud platform offers service agility, operational efficiency and reduced CAPEX/OPEX through MANO.
- Viettel is demonstrating an end-to-end-solution based on Intel server (Xeon-D) with NIC (XXV710-DA2T) that is integrated with an outdoor micro O-RU via an Open Fronthaul Interface. The base station connects with EPC and Viettel’s eNB perform a complete NSA (Option 3X) white-box base station solution and ready for Commercial Deployment. The integrated system is verified using a commercial UE through the attach and speed test.
- Altiostar has teamed up with Airtel and NEC to demonstrate interoperability testing and integration of massive MIMO radio units (O-RU) and virtualized distributed units (O-DU) running on commercial-off-the-shelf (COTS) servers. The demonstration features a commercial end-to-end Open Fronthaul interface based on O-RAN specifications.
- Parallel Wireless is demonstrating 2G, 3G, 4G and 5G O-RAN based macro Open RAN to expand and modernize cellular networks with reduced TCO & simplified maintenance. It’s been proven in rural in 50+ networks globally and is now scalable for urban 2G 3G 4G while unleashing the full 5G potential.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 260 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations. For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218006088/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom